EAGLE EYE HEALTH ALERT: MoPH Qatar Orders Nationwide Recall of Major Medications
Healthcare providers, pharmacies, clinics, and patients across Qatar are advised to review all medication stocks immediately. The affected drugs range from intravenous iron solutions used for treating severe anemia to specialized ophthalmic solutions (eye drops).
Key Highlights & Overview Table
The official MoPH directives, formal circular numbers, affected batches, and regulatory causes are summarized below:
| Announcement Date | Product Name & Strength | Manufacturer / Brand | Official Circular Ref | Primary Reason for Recall |
| Early November 2026 | Ferinject 50 mg/mL (Solution for Injection/Infusion) | Vifor Pharma | MoPH Public Safety Alert / Direct Order | Chemical stability issues and specification deviations. |
| 02 November 2026 | Clasgen 0.05% (Ophthalmic Solution / Eye Drops) | Clasgen Formulations | Circular No (PDC/2026/40) | Sterile manufacturing process non-compliance & data integrity concerns. |
| Late October 2026 | Arla Protein Products (Precautionary Recall) | Arla Foods | Food Safety Dept Directive | Quality control deviations in select local batches. |
Breakdown of Key Recalls
1. Ferinject (Ferric Carboxymaltose) 50 mg/mL Injection
Indication: Intravenous iron replacement therapy used to treat severe iron deficiency anemia when oral iron preparations are ineffective or cannot be used.
Scope of Recall: All batches and current shipments available in local pharmacies, hospitals, and clinics.
Reason: Chemical impurity concerns and stability non-conformance identified during ongoing stability testing.
Action Directed: Healthcare practitioners must halt the administration of current stocks immediately. Patients undergoing IV iron therapy should contact their treating physicians to switch to alternative intravenous iron formulations.
2. Clasgen 0.05% Eye Drops
Indication: Ophthalmic solution used for ocular conditions and inflammation.
Scope of Recall: All imported and distributed batches across the State of Qatar.
Reason: Formal MoPH Circular PDC/2026/40 cited critical findings regarding data integrity and non-compliance with Good Manufacturing Practices (GMP) for sterile ophthalmic products.
Action Directed: Immediate quarantine and return of stock to suppliers. Patients using these eye drops should cease usage and consult their ophthalmologist for a substitute.
Other News:
The Ministry urged the public to refrain from using the product, highlighting the Ministry's dedication to ensuring patient safety and maintaining the quality of pharmaceutical goods.
the ministry urged consumers to stop using the product, in the interest of their health and safety, and confirmed that the necessary measures are being taken to withdraw it from the local market.
Guidelines for Patients, Pharmacists, and Healthcare Providers
MoPH MEDICATION RECALL ACTION PLAN
|
+----------------------------V----------------------------+
| |
v v
[ FOR PATIENTS & CONSUMERS ] [ FOR PHARMACIES & CLINICS ]
* Check home medicine cabinets. * Immediately isolate & quarantine stock.
* Stop taking recalled medications. * Mark batches clearly: "DO NOT DISTRIBUTE".
* Consult treating physician for safe alternatives. * Complete return logs to primary distributors.
* Report adverse effects to MoPH Pharmacovigilance. * Update internal pharmacy inventory systems.
For Patients & Consumers: Check your current prescription bottles, eye drops, and clinic records. If you have been administered or prescribed Ferinject or Clasgen eye drops, contact your clinical care team to arrange a safe, therapeutic alternative.
For Healthcare Providers & Retail Pharmacies: Immediately halt dispensing, pull existing units off retail and storage shelves, and quarantine stock in designated locations prior to supplier return.
Adverse Event Reporting: Any adverse effects or non-compliance incidents should be logged directly via the Qatar Ministry of Public Health online pharmacovigilance portal.
Source & cover image credit: Ministry of Public Health (MoPH)
Comments
Post a Comment